Alnylam Highlights Vutrisiran's Clinical Profile in ATTR-CM at Heart Failure 2026
Event summary
- Alnylam will present new data analyses for vutrisiran in ATTR-CM patients at Heart Failure 2026, May 9-12, 2026.
- Multiple analyses from the Phase 3 HELIOS-B study will underscore vutrisiran's use as a first-line treatment.
- New insights include pharmacodynamic analysis, safety data, and real-world observational study design.
- Presentations cover systolic blood pressure influence, atrial fibrillation effects, and vitamin A safety.
The big picture
Alnylam's presentation at Heart Failure 2026 underscores its push to establish vutrisiran as a cornerstone therapy for ATTR-CM, a rapidly progressive and underdiagnosed disease. The focus on real-world data and subgroup analyses reflects the growing emphasis on personalized medicine in cardiovascular care. With over 500,000 estimated cases worldwide, the market potential for effective ATTR-CM treatments remains substantial.
What we're watching
- Clinical Validation
- Whether the new data will solidify vutrisiran's position as a first-line treatment for ATTR-CM.
- Regulatory Pathway
- The pace at which Alnylam can secure broader approvals based on real-world evidence from DemonsTTRate.
- Competitive Dynamics
- How these findings position vutrisiran against emerging therapies in the ATTR-CM space.
Related topics